Production of intraepidermal microabscesses by topical application of leukotriene B4
- PMID: 6319504
- DOI: 10.1111/1523-1747.ep12259945
Production of intraepidermal microabscesses by topical application of leukotriene B4
Abstract
Leukotriene B4 is a highly potent leukocyte chemotactic compound. It has been identified in chamber fluid and scale from psoriatic skin lesions, in which epidermal neutrophil infiltration is reported to be one of the earliest pathologic events. The ability of leukotriene B4 to reproduce the inflammatory events of psoriasis, by topical application to the skin of normal human volunteers, was thus studied. Persistent visible inflammatory reactions were elicited by application of amounts of leukotriene B4 as low as 5 ng, and the maximum diameters of the reactions were dose-related up to at least 500 ng. The visible reactions appeared 12-24 h after initial application of leukotriene B4, and persisted for several days, leaving brownish pigmentation and scaling at 7 days. Histologic examination showed intraepidermal neutrophil microabscesses at 24 h, but these had resolved by 48 h. A mixed, perivascular neutrophil and mononuclear cell infiltrate was seen in the dermis at 24 h, becoming predominantly mononuclear after 24 h. Nonspecific chemical irritant contact dermatitis was excluded by the absence of reactions to high doses of two chemically similar metabolites of arachidonic acid which lack significant in vitro chemokinetic activity. These experiments provide further evidence for the role of leukotriene B4 in the pathogenesis of psoriasis, and may lead to the development of an experimental model of the inflammatory events in psoriasis, and of a simple in vivo test of neutrophil function.
Similar articles
-
The responses of normal and psoriatic skin to single and multiple topical applications of leukotriene B4.J Invest Dermatol. 1985 May;84(5):421-3. doi: 10.1111/1523-1747.ep12265520. J Invest Dermatol. 1985. PMID: 2987362
-
Epidermal hyperproliferation following the induction of microabscesses by leukotriene B4.Br J Dermatol. 1986 Apr;114(4):409-12. doi: 10.1111/j.1365-2133.1986.tb02843.x. Br J Dermatol. 1986. PMID: 3008801
-
The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis.J Invest Dermatol. 1984 Jul;83(1):70-3. doi: 10.1111/1523-1747.ep12261712. J Invest Dermatol. 1984. PMID: 6330213
-
5-Lipoxygenase activation in psoriasis: a dead issue?Skin Pharmacol. 1993;6(4):292-7. doi: 10.1159/000211152. Skin Pharmacol. 1993. PMID: 8198815 Review.
-
Leukotriene B4: an inflammatory mediator with vascular actions in vivo.Agents Actions Suppl. 1982;11:51-61. Agents Actions Suppl. 1982. PMID: 6295113 Review.
Cited by
-
Perspectives in corticosteroid research.Drugs. 1988;36 Suppl 5:1-8. doi: 10.2165/00003495-198800365-00003. Drugs. 1988. PMID: 3076128 Review.
-
In vitro inhibition of leukotriene B4 formation by exogeneous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxy-eicosatetraenoic acid (15-HETE) by human neutrophils.Arch Dermatol Res. 1988;280(7):430-6. doi: 10.1007/BF00429983. Arch Dermatol Res. 1988. PMID: 2849922
-
Effect of leukotriene B4 and prostaglandin E2 on the adhesion of lymphocytes to endothelial cells.Clin Exp Immunol. 1990 Jul;81(1):160-5. doi: 10.1111/j.1365-2249.1990.tb05308.x. Clin Exp Immunol. 1990. PMID: 2165879 Free PMC article.
-
Cutaneous responses to 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) and 5,12-dihydroxyeicosatetraenoic acid (leukotriene B4) in psoriasis and normal human skin.Arch Dermatol Res. 1987;279(7):427-34. doi: 10.1007/BF00412586. Arch Dermatol Res. 1987. PMID: 2829751
-
LTA4 hydrolase in human skin: decreased activity, but normal concentration in lesional psoriatic skin. Evidence for different LTA4 hydrolase activity in human lymphocytes and human skin.Arch Dermatol Res. 1996 May;288(5-6):217-24. doi: 10.1007/BF02530088. Arch Dermatol Res. 1996. PMID: 8738563
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical